Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROBUPHINE vs BRYNOVIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist. Also inhibits norepinephrine and dopamine reuptake.
Brynoxin is a potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.
Treatment of opioid dependence,Off-label: management of chronic pain,Off-label: treatment of opioid-induced constipation
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
Sublingual: 8 mg to 24 mg once daily initially, then 12-16 mg once daily; maximum 24 mg/day.
Adult: 150 mg orally twice daily.
Terminal elimination half-life: 37 hours (range 24-48 h) due to slow release from tissue binding and enterohepatic recirculation; contributes to prolonged dosing interval (every 4 weeks) and delayed withdrawal onset.
Terminal elimination half-life is 12 hours in patients with normal renal function; prolonged to 24-48 hours in moderate to severe renal impairment (Cr Cl < 30 m L/min).
Primarily metabolized by CYP3A4 and CYP2B6 to norbuprenorphine (active). Glucuronidation via UGT1A1 and UGT2B7.
Primarily metabolized via glucuronidation by UGT1A9 and UGT2B7; minor metabolism by CYP3A4.
Primarily renal (70-80% as unchanged drug and active metabolite norbuprenorphine), biliary/fecal (20-30%)
Renal excretion accounts for 70% of the administered dose as unchanged drug; biliary/fecal excretion accounts for 30%.
96% bound to plasma proteins (primarily alpha- and beta-globulins, minor albumin binding)
85% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Vd: 2.5-3.0 L/kg; large distribution due to high lipophilicity and extensive tissue binding, indicating slow redistribution.
1.5 L/kg, indicating extensive tissue distribution and penetration into peripheral compartments.
Sublingual: 30-50% (due to first-pass metabolism). Transdermal: 15-20% (rate-controlled delivery). Oral: <10% (extensive first-pass) and not clinically used.
Oral: 75% (range: 60-90%) with minimal first-pass metabolism; intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. For severe (Cr Cl <30 m L/min): not recommended.
Cr Cl 30-59 m L/min: 75 mg twice daily; Cr Cl 15-29 m L/min: 50 mg twice daily; Cr Cl <15 m L/min or dialysis: 25 mg once daily.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 75 mg twice daily; Child-Pugh C: 50 mg twice daily.
Weight-based: 0.1-0.2 mg/kg sublingually once daily, titrate up to maximum 0.4 mg/kg/day; maximum 24 mg/day.
Children ≥12 years and ≥40 kg: 150 mg twice daily; <40 kg: 5 mg/kg/dose twice daily (max 150 mg/dose).
Start at lower end of dosing range (e.g., 4-8 mg sublingually once daily) with cautious titration due to increased sensitivity and risk of CNS depression.
No specific dose adjustment, but monitor renal function; start at lower end of dosing range if renal impairment.
Risk of respiratory depression, especially with concurrent use of CNS depressants or in patients with compromised respiratory function. Risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Potential for life-threatening QT prolongation at high doses.
None.
Severe respiratory depression; misuse and abuse potential; neonatal opioid withdrawal syndrome; adrenal insufficiency; hepatotoxicity; QT prolongation; dental decay with sublingual use; opioid withdrawal syndrome with naloxone coadministration.
Ketoacidosis: Monitor for signs of ketoacidosis, including euglycemic ketoacidosis,Lower limb amputation: Consider risk factors prior to initiation; monitor for signs of infection or ulceration
Hypersensitivity to buprenorphine; severe respiratory depression; acute or severe bronchial asthma; paralytic ileus; use of monoamine oxidase inhibitors within 14 days.
Severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease on dialysis,History of serious hypersensitivity reaction to brynoxin or any excipient in the formulation
No specific food interactions are reported for buprenorphine. However, grapefruit and grapefruit juice may theoretically affect metabolism via CYP3A4 inhibition, altering drug levels. Avoid excessive intake.
Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition. Avoid alcohol as it may increase hepatotoxicity risk. Take with food to reduce gastrointestinal upset.
Probupine is classified as FDA Pregnancy Category C. In animal studies, it caused fetal harm (increased resorption, skeletal anomalies) at doses 0.5 times the human dose. There are no adequate human studies. First trimester exposure may be associated with neural tube defects; second and third trimester exposure may cause fetal hydantoin syndrome (craniofacial anomalies, growth retardation, neurodevelopmental delay) and increased risk of hemorrhage due to vitamin K depletion.
First trimester: Human data limited; animal studies show embryotoxicity at supra-therapeutic doses. Avoid unless benefit outweighs risk. Second trimester: No specific malformation signal; monitor fetal growth. Third trimester: Risk of neonatal adaptation syndrome (irritability, feeding difficulties) at delivery if used near term.
Probupine is excreted into breast milk. M/P ratio is approximately 0.45. Infant daily dose is estimated at 1-5% of maternal weight-adjusted dose. Reports of sedation and poor suckling in breastfed infants; cautious use recommended, especially in neonates with UDP-glucuronosyltransferase deficiency.
Excreted in breast milk in low amounts (M/P ratio 0.2–0.4). Considered compatible with breastfeeding; monitor infant for sedation or gastrointestinal effects.
Increased hepatic clearance during pregnancy, especially third trimester, necessitating dose increases up to 30-50% to maintain therapeutic levels. Postpartum dose should be reduced to prepregnancy levels within 2 weeks. Monitor trough levels every 2 weeks during pregnancy and adjust accordingly.
Due to increased volume of distribution and enhanced hepatic clearance in second and third trimesters, the dose may need to be increased by 20–40% to maintain therapeutic plasma concentrations. Therapeutic drug monitoring (trough levels) recommended every 2 weeks with target range 5–15 mcg/m L. Postpartum: reduce dose to pre-pregnancy level within first week.
Probupine is not a recognized drug; verify spelling. If referring to buprenorphine, note that it is a partial mu-opioid agonist used for opioid use disorder and pain. Monitor for respiratory depression, especially when combined with CNS depressants. Due to its partial agonist activity, it has a ceiling effect for respiratory depression. High doses may precipitate withdrawal in opioid-dependent patients. Naloxone may not fully reverse buprenorphine effects; consider higher doses or respiratory support.
Monitor renal function and electrolytes before and during therapy. Use with caution in patients with pre-existing cardiac disease due to risk of QT prolongation. Adjust dose in hepatic impairment (Child-Pugh B or C). Contraindicated with strong CYP3A4 inducers.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,Avoid alcohol, benzodiazepines, and other sedatives unless directed by your physician, as they increase risk of serious side effects.,Do not stop suddenly; withdrawal may occur. Follow a tapering schedule if discontinuing.,Keep out of reach of children and others; misuse can cause addiction, overdose, or death.,Store safely at room temperature, away from moisture and heat.
Take exactly as prescribed; do not skip doses or double up.,Avoid grapefruit and grapefruit juice during treatment.,Report any signs of infection, unusual bruising, or yellowing of skin or eyes.,Use effective contraception during treatment and for 3 months after last dose.,Do not drive if you experience dizziness or blurred vision.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROBUPHINE vs BRYNOVIN, answered by our medical review team.
PROBUPHINE is a Opioid Partial Agonist that works by Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist. Also inhibits norepinephrine and dopamine reuptake.. BRYNOVIN is a Opioid Partial Agonist that works by Brynoxin is a potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROBUPHINE and BRYNOVIN depend on the specific clinical indication. These are both Opioid Partial Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROBUPHINE is: Sublingual: 8 mg to 24 mg once daily initially, then 12-16 mg once daily; maximum 24 mg/day.. The standard adult dose of BRYNOVIN is: Adult: 150 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROBUPHINE and BRYNOVIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROBUPHINE is classified as Category C. Probupine is classified as FDA Pregnancy Category C. In animal studies, it caused fetal harm (increased resorption, skeletal anomalies) at doses 0.5 times the human dose. There are. BRYNOVIN is classified as Category C. First trimester: Human data limited; animal studies show embryotoxicity at supra-therapeutic doses. Avoid unless benefit outweighs risk. Second trimester: No specific malformation . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.